Core Points - Niagen Bioscience, Inc. (NASDAQ: NAGE) is recognized as a global authority on NAD+ with a focus on healthy aging [1] - The company will hold a conference call on November 4, 2025, at 4:30 p.m. ET to discuss its financial results for Q3 2025 [1] - The financial results will be released in a press release after the close of regular stock market trading hours on the same day [1]

Core Insights - U.S. stock futures showed slight gains, with Dow futures up approximately 0.1% [1] Company Performance - PACCAR Inc reported a significant decline in shares, falling 18.3% to $7.64 in pre-market trading after disappointing third-quarter results [1] - The company's quarterly earnings were $1.12 per share, missing the analyst consensus estimate of $1.17 per share [1] - PACCAR's quarterly sales were reported at $6.107 billion, also below the analyst consensus estimate of $6.371 billion [1] Other Stocks Movement - Neuphoria Therapeutics Inc shares plummeted 65.3% to $5.35 after its AFFIRM-1 trial for social anxiety failed to meet endpoints [4] - Citius Pharmaceuticals Inc shares fell 18.2% to $1.48 following a $6 million registered direct offering announcement [4] - Galapagos NV shares declined 15.4% to $28.99 as the company plans to wind down its Cell Therapy Business [4] - Silvercorp Metals Inc shares decreased by 9.9% to $6.35 in pre-market trading [4] - Other notable declines included Theravance Biopharma Inc down 8.6% to $13.07 and Pacira Biosciences Inc down 8.3% to $21.10 [4]

Core Points - Genmab A/S is initiating a cash tender offer to acquire all outstanding common shares of Merus N.V. for $97.00 per share [1] - The offer is part of a transaction agreement dated September 29, 2025, between Genmab, its subsidiary, and Merus [1] - Merus's Board of Directors has recommended that shareholders accept the offer [2] Offer Details - The tender offer will expire at 5:00 p.m. New York City time on December 11, 2025, unless extended [3] - If conditions are met, a subsequent offering period will commence on the first business day following the expiration [3] - The offer is not subject to a financing condition but is subject to other conditions, including a minimum tender condition [4] Shareholder Information - Merus shareholders are advised to review the tender offer documents filed with the SEC before deciding to tender their shares [5] - These documents can be accessed for free on the SEC's website or through the information agent for the tender offer [5] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics [6] - The company has a vision to transform the lives of patients with cancer and serious diseases through advanced antibody medicines by 2030 [6] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with a global presence [7]

Core Viewpoint - Krystal Biotech, Inc. is set to report its third quarter 2025 financial results on November 3, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Krystal Biotech, Inc. is a fully integrated, commercial-stage global biotechnology company focused on the discovery, development, and commercialization of genetic medicines for diseases with high unmet medical needs [3]. - The company's first commercial product, VYJUVEK, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa [3]. - The company is advancing a robust pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3].

Core Insights - Oragenics, Inc. has regained full compliance with NYSE American's continued listing standards, allowing the company to focus on advancing its lead clinical program [1] Group 1 - The company is a clinical-stage biotechnology firm developing brain-targeted therapeutics through proprietary intranasal delivery technology [1] - NYSE American notified Oragenics of compliance regaining effective October 20, 2025 [1]

Group 1 - The SPDR S&P Biotech ETF (NYSEARCA:XBI) is identified as a trending stock this week, with a positive outlook for a breakout in the coming months [1] - Joseph Terranova, a Senior Managing Director at Virtus Investment Partners, plans to purchase the XBI ETF, indicating a target price of around 92, while the current price is 103, suggesting a cautious investment strategy [1] - Terranova believes that the XBI is in the midst of a multi-year breakout, projecting significant growth over the next six to nine months [1] Group 2 - There is a belief that certain AI stocks may offer higher returns with limited downside risk compared to the XBI ETF, indicating a competitive investment landscape [2] - A report is available that highlights an extremely cheap AI stock that benefits from Trump tariffs and onshoring, suggesting alternative investment opportunities [2]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: After months of back-and-forth announcements, Galapagos now plans to wind down its cell therapy business and focus resources on building a pipeline of new medicines through deals and acquisitions. If this plan happens, the Belgian biotechnology company expects to lay off about 365 workers, or more than half of the 704-person workforce it employed ...

Core Insights - Takeda Pharmaceutical Company Limited (NYSE:TAK) has entered a significant research partnership with US biotechnology company Nabla Bio to enhance the use of AI in drug delivery [1][2] - The partnership builds on a previous collaboration initiated in 2022, where Nabla will utilize its AI platform, the Joint Atomic Model (JAM), to develop protein-based treatments for Takeda's early-stage pipeline [2] - Takeda will make an upfront payment in double-digit millions to Nabla, with potential success-based payments exceeding $1 billion [3] Company Overview - Takeda Pharmaceutical Company Limited is a Japanese biotech firm focused on the research, development, and sale of pharmaceuticals, particularly in areas such as gastrointestinal, rare, immune, cancer, and neuropsychiatric diseases [4]

Core Insights - "Buying the dip" can be risky, especially in defensive sectors like healthcare, where stocks may continue to decline for valid reasons [1] Group 1: Moderna - Moderna transitioned from a biotech start-up to a profitable drug company in 2021 and 2022 due to high demand for its COVID-19 vaccine, Spikevax, generating billions in revenue [2] - Demand for COVID-19 vaccines has significantly decreased, leading to a sharp decline in revenue, with last quarter's total sales at just $142 million [3] - Share prices have fallen approximately 35% year-to-date and around 95% from all-time highs in 2021, with potential for further declines unless positive news is announced in the upcoming earnings report on Nov. 6 [4] Group 2: Novo Nordisk - Novo Nordisk, once a leader in GLP-1 therapies, faces increased competition from companies like Eli Lilly, resulting in a forecasted slowdown in earnings growth for this year and 2026 [5] - Earnings per share are projected to increase by only 3.8% this year and 4.8% in 2026, despite a 22% increase in 2024, with potential negative impacts from governmental pressure on GLP-1 prices [6][8] - Although Novo Nordisk appears cheap with a forward P/E ratio of 14 compared to Eli Lilly's 27, its valuation may not be justified given the growth outlook and potential price pressures [8]

Core Insights - The Digital Asset Treasury (DAT) model, popularized by Michael Saylor's Bitcoin Strategy, has led to the establishment of a $344.4 million Aethir-dedicated DAT in collaboration with Predictive Oncology [1][4]. Group 1: Aethir's DAT Model - Aethir's DAT aims to differentiate itself from traditional DATs by actively utilizing assets rather than allowing them to sit idle, thereby supporting the project's infrastructure [2][5]. - The revenue generated from Aethir's GPU rentals will be reinvested to purchase $ATH tokens on the open market, which will help reduce the token supply and link the DAT's performance to actual network usage [5][8]. - The Aethir DAT is designed to be economically sustainable and self-reinforcing, contrasting with the more speculative nature of many existing DATs [6]. Group 2: Predictive Oncology's Role - Predictive Oncology focuses on healthcare, particularly in AI and machine learning for drug discovery and cancer treatment, but has faced declining revenues and increasing net losses since 2021 [4]. - The Aethir treasury represents over 50% of the ATH token's market cap, highlighting its significant impact on the token's valuation [7]. Group 3: Industry Context - Companies utilizing DATs collectively hold over $150 billion in assets, indicating a substantial market presence [7]. - The trend of creating or converting companies into DATs often leads to inflated share prices and short-term shareholder returns, raising concerns about their sustainability [3].